Company News for May 26, 2020

Zacks Equity Research Published on May 26, 2020

Shares of Navidea Biopharmaceuticals, Inc. (NAVB - Free Report) surged 91.3% after the biopharmaceutical company announced positive preliminary results from the second interim analysis of its ongoing NAV3-31 Phase 2B study.
Shares of Xeris Pharmaceuticals, Inc. (XERS - Free Report) soared 28% after the specialty pharmaceutical company reported findings from outpatient portion of Phase 2 proof-of-concept study of its developmental ready-to-use glucagon in patients at risk of postprandial hypoglycemia following bariatric surgery.
Shares of T2 Biosystems, Inc. (TTOO - Free Report) rose 12.8% after the in vitro diagnostics companysaid it expects to ship first SARS-CoV-2 tests to American customers as early as June-end.
Shares of Splunk Inc. gained 12.7% after the company reported first-quarter fiscal 2021 non-GAAP loss of 56 cents per share, which was lesser than the Zacks Consensus Estimate of a loss of 57 cents.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.